Daiichi Sankyo Company, Limited

4568.T
Drug Manufacturers - General
2026/10/30 12:01 Updated
Market Cap: $30.3B (¥4.8T)
Stock Price: $16.68 (¥2,627)
Exchange Rate: 1 USD = ¥157.48

Supplementary Financial Materials (Fiscal Year 2026 Q2 Results)

Supplementary materials for the Fiscal Year 2026 Q2 results. Revenue shows a structure below the prior year, while core operating profit increased. Includes analysis of foreign exchange effects, contributions from new businesses, and segment trends such as EU specialty.

Importance:
Page Updated: October 30, 2026
IR Disclosure Date: October 30, 2026

Key Figures

  • Revenue: 11,672 hundred million yen
  • Core Operating Profit: 2,213 hundred million yen
  • Net Income Attributable to Owners of Parent: 1,515 hundred million yen

AI要約

Overview of Results

These are consolidated supplementary materials for the Fiscal Year 2026 Q2 results. Overall revenue shows fluctuations compared with the prior year results. Core operating profit increased significantly year-over-year, and it is necessary to examine changes in the composition of global product sales along with the impacts of foreign exchange and adjustment items.

Outlook and Impact for Investors

Investors should monitor the impact on the medium-term plan considering foreign exchange effects, segment-level contributions, and the contribution of key products. Attention should also be paid to the increase in cash and cash equivalents and trends in free cash flow.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Daiichi Sankyo Company, Limited

Company overview · Stock price · Financial data · All IR

View company page →